Aditxt Inc. Strengthens Board with Appointment of Evofem CEO Saundra Pelletier
Aditxt Inc. (NASDAQ: ADTX) has appointed Saundra Pelletier, CEO of Evofem Biosciences, to its Board of Directors, signaling a strategic focus on women's health and commercialization efforts.
Aditxt Inc. (NASDAQ: ADTX) has announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences (OTCPK: EVFM), to its Board of Directors. This move underscores Aditxt's commitment to advancing its commercialization strategy and enhancing its focus on women's health. Pelletier's extensive experience in the global pharmaceutical industry, particularly in women's reproductive health, positions her as a valuable addition to the board. Her leadership at Evofem saw the approval and commercial success of Phexxi(R) and the acquisition of SOLOSEC(R), contributing to four consecutive years of net sales growth.
The appointment is significant as Aditxt seeks to expand its innovation platform, which includes programs dedicated to immune health, precision health, and upcoming initiatives in public health and women's health. The company's collaboration with Appili Therapeutics Inc. and a merger agreement with Evofem are part of its strategy to address urgent health challenges. Pelletier's expertise and leadership in women's health could play a pivotal role in Aditxt's efforts to innovate and commercialize health solutions, potentially impacting the healthcare industry and improving patient outcomes.